LEXINGTON, Mass., May 14, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced its support of the first global hereditary

COMPACT (Clinical Studies for Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-inhibitor Replacement T

EXTON, Pa., March 29, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM), the maker of Cinryze® (C1 esterase inhibitor [human]), today launched the hereditary angioedema (HAE) Family

ORLANDO, Fla., March 6, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) today announced the presentation of positive data from

ORLANDO, Fla., March 6, 2012 /PRNewswire/ --CSL Behring announced today that treatment with Berinert®,